Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.

Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, Grant S.

Blood. 2003 Sep 1;102(5):1824-32. Epub 2003 May 8.

5.
6.

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S.

Cancer Res. 2004 Apr 1;64(7):2590-600.

7.
8.

Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases.

Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN.

Blood. 2003 Jul 1;102(1):269-75. Epub 2003 Mar 6.

11.
13.

Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.

Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P, Grant S.

Blood. 2004 Apr 1;103(7):2761-70. Epub 2003 Nov 26.

14.

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.

Premkumar DR, Arnold B, Pollack IF.

Mol Carcinog. 2006 May;45(5):288-301.

PMID:
16550610
17.

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K.

Cancer Res. 2004 May 15;64(10):3645-52.

18.

Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.

Premkumar DR, Arnold B, Jane EP, Pollack IF.

Mol Carcinog. 2006 Jan;45(1):47-59.

PMID:
16267832
19.

Supplemental Content

Support Center